<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>GLUCAGEN- glucagon hydrochloride 
			 </strong><br><strong>GLUCAGEN- glucagon hydrochloride injection, powder, for solution </strong><br>Boehringer Ingelheim Pharmaceuticals, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use GlucaGen safely and effectively. See full prescribing information for GlucaGen.<br>GlucaGen<span class="Sup">®</span> (glucagon [rDNA origin] for injection)<br>Initial U.S. Approval: 1998</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">GlucaGen is an antihypoglycemic agent and a gastrointestinal motility inhibitor indicated for: </p>
<dl>
<dt>•</dt>
<dd>Treatment of severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> (<a href="#i4i_indications_duplicate_id_cee3a53b-cca4-4400-903f-90aad95bfbb1">1.1</a>)</dd>
<dt>•</dt>
<dd>Use as a diagnostic aid (<a href="#i4i_indications_duplicate_id_f1de3cb3-384e-49a2-9153-4ad3995e5c07">1.2</a>)</dd>
</dl>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta"><span class="Bold">Treatment of severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> (GlucaGen HypoKit)</span> </p>
<dl>
<dt>•</dt>
<dd>Reconstitute before administration. (<a href="#i4i_dosage_admin_duplicate_id_e96450a5-8bff-4ed3-bdb8-2157b163db53">2.1</a>)</dd>
<dt>•</dt>
<dd>Inject 1 mL (adults and children, weighing more than 55 lbs (25 kg)) or 0.5 mL (children weighing less than 55 lbs (25 kg)) subcutaneously, intramuscularly, or intravenously. (<a href="#i4i_dosage_admin_duplicate_id_e96450a5-8bff-4ed3-bdb8-2157b163db53">2.1</a>)</dd>
<dt>•</dt>
<dd>If the weight is not known: Children younger than 6 years should be given 0.5 mL and children 6 years and older should be given 1 mL. (<a href="#i4i_dosage_admin_duplicate_id_e96450a5-8bff-4ed3-bdb8-2157b163db53">2.1</a>)</dd>
<dt>•</dt>
<dd>Seek emergency assistance immediately after subcutaneous or intramuscular injection of glucagon. Glucagon injection may be repeated while waiting for emergency assistance. (<a href="#i4i_dosage_admin_duplicate_id_e96450a5-8bff-4ed3-bdb8-2157b163db53">2.1</a>)</dd>
<dt>•</dt>
<dd>Intravenous glucose MUST be administered if the patient fails to respond to glucagon. (<a href="#i4i_dosage_admin_duplicate_id_e96450a5-8bff-4ed3-bdb8-2157b163db53">2.1</a>)</dd>
<dt>•</dt>
<dd>When the patient responds to treatment, give oral carbohydrates to restore the liver glycogen and prevent recurrence of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. (<a href="#i4i_dosage_admin_duplicate_id_e96450a5-8bff-4ed3-bdb8-2157b163db53">2.1</a>)</dd>
</dl>
<p class="Highlighta"><span class="Bold">Use as a diagnostic aid (GlucaGen Diagnostic Kit and GlucaGen 10-Pack)</span> </p>
<dl>
<dt>•</dt>
<dd>Reconstitute before administration. (<a href="#ID_0bf044db-db87-42e9-ab06-b9b1c7b96084">2.2</a>)</dd>
<dt>•</dt>
<dd>The dose ranges from 0.2 mg to 2 mg depending on the diagnostic technique and the route of administration. (<a href="#ID_0bf044db-db87-42e9-ab06-b9b1c7b96084">2.2</a>)</dd>
<dt>•</dt>
<dd>After the end of the diagnostic procedure, give oral carbohydrates to patients who have been fasting, if this is compatible with the diagnostic procedure applied. (<a href="#ID_0bf044db-db87-42e9-ab06-b9b1c7b96084">2.2</a>)</dd>
</dl>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Each vial contains 1 mg/mL (1 unit/mL) GlucaGen when reconstituted with Sterile Water for Reconstitution or Sterile Water for Injection, USP. (<a href="#i4i_dosage_form_strength_id_b5289c05-f7f1-480f-98ec-3631443e5e21">3</a>)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Do not use in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to glucagon or lactose (<a href="#i4i_contraindications_id_088a6776-8610-483b-a467-b4338b1faba0">4</a>)</dd>
<dt>•</dt>
<dd>Do not use in patients with <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span> (<a href="#i4i_contraindications_id_088a6776-8610-483b-a467-b4338b1faba0">4</a>)</dd>
<dt>•</dt>
<dd>Do not use in patients with <span class="product-label-link" type="condition" conceptid="4102701" conceptname="Insulinoma">insulinoma</span> (<a href="#i4i_contraindications_id_088a6776-8610-483b-a467-b4338b1faba0">4</a>)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Administer cautiously to patients suspected of having <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span>, <span class="product-label-link" type="condition" conceptid="4102701" conceptname="Insulinoma">insulinoma</span> or <span class="product-label-link" type="condition" conceptid="4028719" conceptname="Glucagonoma">glucagonoma</span> due to risk of secondary <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. Glucagon may release catecholamines from <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytomas</span> and is contraindicated in patients with this condition. (<a href="#i4i_section_id_619a8c44-2bdd-4d5f-9a43-9e4dd0cd51cb">5.1</a>, <a href="#i4i_section_id_9bb95c7a-d623-4605-a346-0b8749b0e69e">5.2</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span> may occur and include generalized <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and in rare cases <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic shock</span> with breathing difficulties, and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. (<a href="#i4i_section_id_5512e382-5254-484d-9ce7-f88a208e9de8">5.3</a>)</dd>
<dt>•</dt>
<dd>In order for GlucaGen treatment to reverse <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, there must be adequate amounts of glycogen stored in the liver. GlucaGen should be used with caution in patients with conditions resulting in low levels of releasable glucose in the liver. (<a href="#i4i_section_id_7481580a-059c-4638-a9cf-bf14515d57aa">5.4</a>) </dd>
<dt>•</dt>
<dd>Use caution when glucagon is used as a diagnostic aid in diabetic patients because it may cause <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>. (<a href="#i4i_section_id_7481580a-059c-4638-a9cf-bf14515d57aa">5.4</a>)</dd>
<dt>•</dt>
<dd>Use with caution in patients with known cardiac disease, as glucagon increases myocardial oxygen demand. (<a href="#i4i_section_id_3859b21e-b92d-46dd-9d41-4078fd13fff0">5.5</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Adverse reactions seen with GlucaGen are:  </p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (<a href="#i4i_adverse_effects_id_d2c920c2-86f3-4aa1-83ca-ef32b3aa1e6b">6</a>)</dd>
<dt>•</dt>
<dd>Temporary increase in blood pressure and pulse may occur after administration. (<a href="#i4i_adverse_effects_id_d2c920c2-86f3-4aa1-83ca-ef32b3aa1e6b">6</a>)</dd>
</dl>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Novo Nordisk Inc. at 1-800-727-6500 or FDA at 1-800-FDA-1088 or <span class="Italics"><a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</a></span><span class="Underline">.</span></span> </p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Beta-blockers may cause a greater increase in both pulse and blood pressure after administration. (<a href="#i4i_interactions_id_5778f234-1179-49a0-a219-09708908a642">7.1</a>)</dd>
<dt>•</dt>
<dd>Glucagon may lose its ability to raise blood glucose or may produce <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> when given with indomethacin. (<a href="#i4i_interactions_id_5778f234-1179-49a0-a219-09708908a642">7.2</a>)</dd>
<dt>•</dt>
<dd>Coadministration with an anticholinergic drug is not recommended due to increased gastrointestinal side effects. (<a href="#i4i_section_id_2e649fe0-89f7-4d7c-a828-5b99826ac814">7.3</a>)</dd>
<dt>•</dt>
<dd>Glucagon may increase the anticoagulant effect of warfarin. (<a href="#i4i_interactions_id_5778f234-1179-49a0-a219-09708908a642">7.4</a>)</dd>
<dt>•</dt>
<dd>Insulin reacts antagonistically towards glucagon. (<a href="#i4i_section_id_6350ee4a-81dd-4025-94e0-33265f0f2e16">7.5</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Nursing mothers: unknown whether drug is excreted in human milk, therefore caution should be exercised. (<a href="#i4i_nursing_mothers_id_ed61496c-aeba-4a2f-9f50-223b398e1c85">8.3</a>)</dd>
<dt>•</dt>
<dd>Pediatrics: reported safe and effective for treatment of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. Safety and effectiveness for use as a diagnostic aid have not been established. (<a href="#i4i_pediatric_use_id_69a2ec81-95af-4b26-8442-02d3b809412c">8.4</a>)</dd>
</dl></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 12/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 Treatment of severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span></a></h2>
<h2><a href="#section-1.2" class="toc">1.2 Use as a diagnostic aid</a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Treatment of severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span></a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Use as a diagnostic aid</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">Pheochromocytoma</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="4102701" conceptname="Insulinoma">Insulinoma</span> and <span class="product-label-link" type="condition" conceptid="4028719" conceptname="Glucagonoma">Glucagonoma</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Glycogen Stores and <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Cardiac Disease</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Laboratory Tests</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Beta-blockers</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Indomethacin</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Anticholinergic Drugs</a></h2>
<h2><a href="#section-7.4" class="toc">7.4 Warfarin</a></h2>
<h2><a href="#section-7.5" class="toc">7.5 Insulin</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-13.1" class="toc">16.1 How Supplied</a></h2>
<h2><a href="#section-13.2" class="toc">16.2 Recommended Storage</a></h2>
<h1><a href="#section-14" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-14.1" class="toc">17.1 Physician Instructions</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_7ee42d4a-ebef-43fc-ac0d-ce655d283713"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_indications_duplicate_id_cee3a53b-cca4-4400-903f-90aad95bfbb1"></a><a name="section-1.1"></a><p></p>
<h2>1.1 Treatment of severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span></h2>
<p class="First">GlucaGen is used to treat severe hypoglycemic (low blood sugar) reactions which may occur in patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus treated with insulin. Because GlucaGen depletes glycogen stores, the patient should be given supplemental carbohydrates as soon as he/she awakens and is able to swallow, especially children or adolescents. Medical evaluation is recommended for all patients who experience severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_indications_duplicate_id_f1de3cb3-384e-49a2-9153-4ad3995e5c07"></a><a name="section-1.2"></a><p></p>
<h2>1.2 Use as a diagnostic aid</h2>
<p class="First">GlucaGen is indicated for use during radiologic examinations to temporarily inhibit movement of the gastrointestinal tract. Glucagon is as effective for this examination as are the anticholinergic drugs. However, the addition of the anticholinergic agent may result in increased side effects. After the end of the diagnostic procedure, give oral carbohydrates to patients who have been fasting, if this is compatible with the diagnostic procedure applied.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_297eeb4e-5bc9-4103-8b1a-58c35a729f75"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span class="Bold">For GlucaGen HypoKit:</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_dosage_admin_duplicate_id_e96450a5-8bff-4ed3-bdb8-2157b163db53"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Treatment of severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span></h2>
<dl>
<dt>1.</dt>
<dd>Using the supplied prefilled syringe, carefully insert the needle through the rubber stopper of the vial containing GlucaGen powder and inject all the liquid from the syringe into the vial.</dd>
<dt>2.</dt>
<dd>Shake the vial gently until the powder is completely dissolved and no particles remain in the fluid. The reconstituted fluid should be clear and of water-like consistency.</dd>
<dt>3.</dt>
<dd>The reconstituted GlucaGen gives a concentration of approximately 1 mg/mL glucagon.</dd>
<dt>4.</dt>
<dd>The reconstituted GlucaGen should be used immediately after reconstitution.</dd>
<dt>5.</dt>
<dd>Inject 1 mL (adults and children, weighing more than 55 lbs (25 kg)) or 0.5 mL (children weighing less than 55 lbs (25 kg)) subcutaneously, intramuscularly, or intravenously. If the weight is not known: children younger than 6 years should be given a 0.5 mL and children 6 years and older should be given 1 mL. </dd>
<dt>6.</dt>
<dd><span class="Underline">Discard any unused portion.</span></dd>
<dt>7.</dt>
<dd>Emergency assistance should be sought immediately after subcutaneous or intramuscular injection of glucagon.</dd>
<dt>8.</dt>
<dd>The glucagon injection may be repeated using a new kit while waiting for emergency assistance.</dd>
<dt>9.</dt>
<dd>Intravenous glucose MUST be administered if the patient fails to respond to glucagon.</dd>
<dt>10.</dt>
<dd>When the patient has responded to the treatment, give oral carbohydrates to restore the liver glycogen and prevent recurrence of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>.</dd>
</dl>
<p class="First"><span class="Bold">For GlucaGen Diagnostic Kit and the GlucaGen 10-pack:</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_0bf044db-db87-42e9-ab06-b9b1c7b96084"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Use as a diagnostic aid</h2>
<dl>
<dt>1.</dt>
<dd>GlucaGen should be reconstituted with 1 mL of Sterile Water for Reconstitution (if supplied) or 1 mL of Sterile Water for Injection, USP. Using a syringe, withdraw all of the Sterile Water for Reconstitution (if supplied) or 1 mL Sterile Water for Injection, USP and inject into the GlucaGen vial.  </dd>
<dt>2.</dt>
<dd>Shake the vial gently until the powder is completely dissolved and no particles remain in the fluid.  The reconstituted fluid should be clear and of water-like consistency.  </dd>
<dt>3.</dt>
<dd>The reconstituted GlucaGen gives a concentration of approximately 1 mg/mL glucagon.  </dd>
<dt>4.</dt>
<dd>The reconstituted GlucaGen should be used immediately after reconstitution.  </dd>
<dt>5.</dt>
<dd>GlucaGen must be administered by medical personnel.</dd>
<dt>6.</dt>
<dd><span class="Underline">Discard any unused portion.</span></dd>
<dt>7.</dt>
<dd>Onset of action after an injection will depend on the organ under examination and route of administration <span class="Italics"><a href="#i4i_pharmacodynamics_id_9e1baba9-e725-4896-9d68-10a96424edda">[see Pharmacodynamics (12.2)]</a></span>.  </dd>
<dt>8.</dt>
<dd>The usual diagnostic dose for relaxation of the stomach, duodenal bulb, duodenum, and small bowel is 0.2 mg to 0.5 mg given intravenously or 1 mg given intramuscularly; the usual dose to relax the colon is 0.5 mg to 0.75 mg intravenously and 1 mg to 2 mg intramuscularly<span class="Italics"><a href="#i4i_pharmacodynamics_id_9e1baba9-e725-4896-9d68-10a96424edda">[see Pharmacodynamics (12.2)]</a></span>.  </dd>
<dt>9.</dt>
<dd>After the end of the diagnostic procedure, give oral carbohydrates to patients who have been fasting, if this is compatible with the diagnostic procedure applied.</dd>
</dl>
<p class="First"><span class="Bold">The GlucaGen Diagnostic Kit and the GlucaGen 10-pack presentations are intended only for use by healthcare providers as a diagnostic aid. The GlucaGen Diagnostic Kit and the GlucaGen 10-pack presentations are not intended for use by patients to treat severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> because they are not packaged with a syringe and diluent necessary for rapid preparation and administration during an emergency outside of a healthcare facility. </span></p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_b5289c05-f7f1-480f-98ec-3631443e5e21"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">GlucaGen is supplied in a vial, alone, or accompanied by Sterile Water for Reconstitution (1 mL) also in a vial (10 pack or diagnostic kit). It is also supplied as GlucaGen HypoKit<span class="Sup">®</span>, a presentation with a disposable prefilled syringe containing 1 mL Sterile Water for Reconstitution. When the glucagon powder is reconstituted with Sterile Water for Reconstitution (if supplied) or with Sterile Water for Injection, USP, it forms a solution of 1 mg/mL (1 unit/mL) glucagon for subcutaneous, intramuscular, or intravenous injection.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_088a6776-8610-483b-a467-b4338b1faba0"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">GlucaGen is contraindicated in patients with:</p>
<dl>
<dt>•</dt>
<dd>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to glucagon, lactose or any other constituent in GlucaGen</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">Pheochromocytoma</span> <span class="Italics"><a href="#i4i_section_id_619a8c44-2bdd-4d5f-9a43-9e4dd0cd51cb">[see Warnings and Precautions (5.1)]</a></span>
</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4102701" conceptname="Insulinoma">Insulinoma</span> <span class="Italics"><a href="#i4i_section_id_9bb95c7a-d623-4605-a346-0b8749b0e69e">[see Warnings and Precautions (5.2)]</a></span>
</dd>
</dl>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_00ccfec7-7e3d-4a8d-bab5-347a8bb7f81b"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_619a8c44-2bdd-4d5f-9a43-9e4dd0cd51cb"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">Pheochromocytoma</span></h2>
<p class="First">Glucagon is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span> because Glucagon may stimulate the release of catecholamines from the tumor. If the patient develops a dramatic increase in blood pressure, 5 to 10 mg of phentolamine mesylate has been shown to be effective in lowering blood pressure for the short time that control would be needed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9bb95c7a-d623-4605-a346-0b8749b0e69e"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="4102701" conceptname="Insulinoma">Insulinoma</span> and <span class="product-label-link" type="condition" conceptid="4028719" conceptname="Glucagonoma">Glucagonoma</span></h2>
<p class="First">GlucaGen should be administered cautiously to patients suspected of having <span class="product-label-link" type="condition" conceptid="4102701" conceptname="Insulinoma">insulinoma</span> or <span class="product-label-link" type="condition" conceptid="4028719" conceptname="Glucagonoma">glucagonoma</span>. In patients with <span class="product-label-link" type="condition" conceptid="4102701" conceptname="Insulinoma">insulinoma</span>, intravenous administration of glucagon may produce an initial increase in blood glucose; however, glucagon administration may directly or indirectly (through an initial rise in blood glucose) stimulate exaggerated insulin release from an <span class="product-label-link" type="condition" conceptid="4102701" conceptname="Insulinoma">insulinoma</span>. A patient developing symptoms of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> after a dose of glucagon should be given glucose orally or intravenously, whichever is most appropriate. Caution should also be observed in administering GlucaGen to patients with <span class="product-label-link" type="condition" conceptid="4028719" conceptname="Glucagonoma">glucagonoma</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5512e382-5254-484d-9ce7-f88a208e9de8"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span> may occur and include generalized <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and in some cases <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic shock</span> with breathing difficulties, and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. The <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> have generally occurred in association with endoscopic examination during which patients often received other agents including contrast media and local anesthetics. The patients should be given standard treatment for <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> including an injection of epinephrine if they encounter respiratory difficulties after GlucaGen injection.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7481580a-059c-4638-a9cf-bf14515d57aa"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Glycogen Stores and <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></h2>
<p class="First">In order for GlucaGen treatment to reverse <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, adequate amounts of glucose must be stored in the liver (as glycogen). Therefore, GlucaGen should be used with caution in patients with conditions such as prolonged fasting, <span class="product-label-link" type="condition" conceptid="443082" conceptname="Starvation">starvation</span>, <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal insufficiency</span> or chronic <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> because these conditions result in low levels of releasable glucose in the liver and an inadequate reversal of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> by GlucaGen treatment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3859b21e-b92d-46dd-9d41-4078fd13fff0"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Cardiac Disease</h2>
<p class="First">Caution should be observed when glucagon is used as an adjunct in endoscopic or radiographic procedures to inhibit gastrointestinal motility in patients with known cardiac disease.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3ecb3642-b33a-4524-b796-853c0d9f9fbd"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Laboratory Tests</h2>
<p class="First">Blood glucose measurements may be considered to monitor the patient’s response.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_d2c920c2-86f3-4aa1-83ca-ef32b3aa1e6b"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">Side effects may include <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> at doses above 1 mg or with rapid injection. <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> has been reported up to 2 hours after administration in patients receiving GlucaGen as premedication for upper GI endoscopy procedures. Glucagon exerts positive inotropic and chronotropic effects and may, therefore, cause <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> and <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. Adverse reactions indicating toxicity of GlucaGen have not been reported. A temporary increase in both blood pressure and pulse rate may occur following the administration of glucagon. Patients taking beta-blockers might be expected to have a greater increase in both pulse and blood pressure, an increase of which will be temporary because of glucagon’s short half-life <span class="Italics"><a href="#i4i_section_id_ab065e5c-18ee-4c42-b438-3750394b0027">[see Drug Interactions (7.1)]</a></span>. The increase in blood pressure and pulse rate may require therapy in patients with <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span> or <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> <span class="Italics"><a href="#i4i_section_id_619a8c44-2bdd-4d5f-9a43-9e4dd0cd51cb">[see Warnings and Precautions (5.1)]</a>.</span> <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic reactions</span> may occur in some cases <span class="Italics"><a href="#i4i_section_id_5512e382-5254-484d-9ce7-f88a208e9de8">[see Warnings and Precautions (5.3)]</a></span>.</p>
<p>The following adverse reactions have been identified during postapproval use of GlucaGen. Because these adverse reactions are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency.</p>
<a name="_Refid_5d9bcd77-d5c9-4b03-9967-1f1f34d9f"></a><table width="100%">
<caption><span>Table 1 Frequency of Adverse Reactions</span></caption>
<col width="53%">
<col width="47%">
<tbody class="Headless">
<tr class="First"><td class="Botrule Toprule" colspan="2"><p class="First"><span class="Bold">Treatment of severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span></span></p></td></tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="Bold">Frequency (%)</span></p></td>
<td class="Botrule"><p class="First"><span class="Bold">Adverse Reaction</span></p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">&lt; 10</p></td>
<td class="Botrule"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">&lt; 1</p></td>
<td class="Botrule"><p class="First"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
</tr>
<tr><td class="Botrule" colspan="2"><p class="First"><span class="Bold">Use as a diagnostic aid</span></p></td></tr>
<tr>
<td class="Botrule Rrule"><p class="First">&lt; 10</p></td>
<td class="Botrule"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">&lt; 1</p></td>
<td class="Botrule"><p class="First"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">&lt; 1</p></td>
<td class="Botrule"><p class="First"><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></p></td>
</tr>
<tr class="Last">
<td class="Botrule Rrule"><p class="First">&lt;1</p></td>
<td class="Botrule"><p class="First"><span class="product-label-link" type="condition" conceptid="380688" conceptname="Hypoglycemic coma">Hypoglycemic coma</span></p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_5778f234-1179-49a0-a219-09708908a642"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ab065e5c-18ee-4c42-b438-3750394b0027"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Beta-blockers</h2>
<p class="First">Patients taking beta-blockers might be expected to have a greater increase in both pulse and blood pressure, an increase of which will be temporary because of glucagon’s short half-life. The increase in blood pressure and pulse rate may require therapy in patients with <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span> or <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5a252251-cc61-4323-935e-2da8df3ea910"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Indomethacin</h2>
<p class="First">When used with indomethacin, glucagon may lose its ability to raise blood glucose or may even produce <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. Therefore, caution should be exercised for patients taking indomethacin when glucagon will be administered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2e649fe0-89f7-4d7c-a828-5b99826ac814"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Anticholinergic Drugs</h2>
<p class="First">Coadministration with an anticholinergic drug is not recommended due to increased gastrointestinal side effects.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8e4fb9d2-1835-47d8-a823-a8644c6446c5"></a><a name="section-7.4"></a><p></p>
<h2>7.4 Warfarin</h2>
<p class="First">Glucagon may increase the anticoagulant effect of warfarin. Therefore, caution should be exercised for patients taking warfarin when glucagon will be administered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6350ee4a-81dd-4025-94e0-33265f0f2e16"></a><a name="section-7.5"></a><p></p>
<h2>7.5 Insulin</h2>
<p class="First">Insulin reacts antagonistically towards glucagon. Therefore, caution should be exercised when glucagon is used as a diagnostic aid in <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_f8a613c8-ab63-41de-8fcc-add137ab1070"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_17311e81-c67c-4995-9562-e81f81b48dea"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">Pregnancy Category B. Reproduction studies were performed in rats and rabbits at GlucaGen doses of 0.4, 2.0, and 10 mg/kg. These doses represent exposures of up to 100 and 200 times the human dose based on mg/m<span class="Sup">2</span> for rats and rabbits, respectively, and revealed no evidence of harm to the fetus. There are, however, no adequate and well-controlled studies in pregnant women. Glucagon does not cross the human placenta barrier.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_ed61496c-aeba-4a2f-9f50-223b398e1c85"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when GlucaGen is administered to a nursing woman. No clinical studies have been performed in nursing mothers, however, GlucaGen is a peptide and intact glucagon is not absorbed from the GI tract. Therefore, even if the infant ingested glucagon it would be unlikely to have any effect on the infant. Additionally, GlucaGen has a short plasma half-life thus limiting amounts available to the child. Glucagon does not cross the human placental barrier.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_69a2ec81-95af-4b26-8442-02d3b809412c"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">For the treatment of severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>: The use of glucagon in pediatric patients has been reported to be safe and effective.</p>
<p>For use as a diagnostic aid: Safety and effectiveness in pediatric patients have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_6cf55454-3e68-4183-80df-4f399df1166c"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">No reports of overdosage with GlucaGen have been reported. If overdosage occurs, the patient may experience <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, inhibition of GI tract motility, increase in blood pressure and pulse rate. In case of suspected overdosing, the serum potassium may decrease and should be monitored and corrected if needed. If the patient develops a dramatic increase in blood pressure, phentolamine mesylate has been shown to be effective in lowering blood pressure for the short time that control would be needed.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_d1481ab7-40d7-4359-9afc-72c6856d37db"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">GlucaGen (glucagon [rDNA origin] for injection) is an antihypoglycemic agent and a gastrointestinal motility inhibitor. It is produced by expression of recombinant DNA in a <span class="Italics">Saccharomyces cerevisiae</span> vector with subsequent purification. The chemical structure of the glucagon in GlucaGen is identical to human glucagon and to glucagon extracted from beef and pork pancreas. Glucagon with the empirical formula of C<span class="Sub">153</span>H<span class="Sub">225</span>N<span class="Sub">43</span>O<span class="Sub">49</span>S, and a molecular weight of 3483, is a single-chain polypeptide containing 29 amino acid residues. The structure of glucagon is:</p>
<div class="Figure">
<a name="id727"></a><img alt="Structural formula of GlucaGen." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ff16e4b1-3668-4cb4-91a4-77ee509cd6f6&amp;name=91272300-e7bb-4491-86db-e840126c888b-01.jpg">
</div>
<p>GlucaGen is a sterile, lyophilized white powder in a 2 mL vial. The reconstituted solution contains glucagon as hydrochloride 1 mg/mL (1 unit/mL) and lactose monohydrate (107 mg). GlucaGen is supplied at pH 2.5-3.5 and is soluble in water.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_608f9d53-194a-4200-8938-dee7369c94b7"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_12f8f61c-162f-4cf1-bae2-52d130b8e693"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First"><span class="Bold">Antihypoglycemic Action:</span> Glucagon induces liver glycogen breakdown, releasing glucose from the liver. Hepatic stores of glycogen are necessary for glucagon to produce an antihypoglycemic effect.</p>
<p><span class="Bold">Gastrointestinal Motility Inhibition:</span> Extra hepatic effects of glucagon include relaxation of the smooth muscle of the stomach, duodenum, small bowel, and colon.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="i4i_pharmacodynamics_id_9e1baba9-e725-4896-9d68-10a96424edda"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First"><span class="Bold">For the treatment of severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>:</span></p>
<p>Blood glucose concentration rises within 10 minutes of injection and maximal concentrations are attained at approximately 30 minutes after injection (see Figure 1). The duration of hyperglycemic action after intravenous or intramuscular injection is 60 – 90 minutes.</p>
<div class="Figure">
<a name="id759"></a><img alt="Graph " src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ff16e4b1-3668-4cb4-91a4-77ee509cd6f6&amp;name=91272300-e7bb-4491-86db-e840126c888b-02.jpg">
</div>
<p><span class="Bold">Figure 1. Recovery from Insulin Induced <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> (mean blood glucose) After Intramuscular Injection of 1 mg GlucaGen in Type I Diabetic Men</span></p>
<p><span class="Bold">For use as a diagnostic aid:</span></p>
<a name="_Refid_4ce4a415-9ac2-4bac-adae-94b6a5ac0"></a><table width="100%">
<caption><span>Table 2 Pharmacodynamic Properties of Glucagon</span></caption>
<col width="16%">
<col width="21%">
<col width="21%">
<col width="21%">
<col width="20%">
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>The usual diagnostic dose for relaxation of the stomach, duodenal bulb, duodenum, and small bowel is 0.2 – 0.5 mg given intravenously or 1 mg given intramuscularly; the usual dose to relax the colon is 0.5 – 0.75 mg intravenously and 1 – 2 mg intramuscularly.</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>Note: The time of maximal glucose concentration for GlucaGen administered subcutaneously is 30-45 minutes.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Route of Administration</span></p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Dose</span><a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Time of Maximal Glucose Concentration</span></p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Time of Onset of Action for GI Smooth <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">Muscle Relaxation</span></span></p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Duration of Smooth <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">Muscle Relaxation</span></span><a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" rowspan="2"><p class="First"><span class="Bold">IV</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">0.25-0.5 mg (0.25-0.5 units)</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">5-20 minutes</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">45 seconds</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">9-17 minutes</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">2 mg (2 units)</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">5-20 minutes</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">45 seconds</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">22-25 minutes</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" rowspan="2"><p class="First"><span class="Bold">IM</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">1 mg (1 unit)</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">30 minutes</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">8-10 minutes</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">12-27 minutes</span></p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">2 mg (2 units)</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">30 minutes</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">4-7 minutes</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">21-32 minutes</span></p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_830f47b9-1da1-4ef4-ad7f-3007e11730cd"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">Intramuscular injection of 1 mg GlucaGen resulted in a mean C<span class="Sub">max</span> (CV%) of 1686 pg/mL (43%) and median T<span class="Sub">max</span> of 12.5 minutes. The mean apparent half-life of 45 minutes after intramuscular injection probably reflects prolonged absorption from the injection site. Glucagon is degraded in the liver, kidney, and plasma. </p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_a4b867da-b7b0-484c-bd2e-003bea73be15"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_7e5fb6e6-0b04-42a0-b70d-1c95c690ca43"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long term studies in animals to evaluate carcinogenic potential have not been performed. Several studies have been conducted to evaluate the mutagenic potential of glucagon. The mutagenic potential tested in the Ames and human lymphocyte assays, was borderline positive under certain conditions for both glucagon (pancreatic) and glucagon (rDNA) origin. <span class="Italics">In vivo</span>, very high doses (100 and 200 mg/kg) of glucagon (both origins) gave a slightly higher incidence of micronucleus formation in male mice but there was no effect in females. The weight of evidence indicates that GlucaGen is not different from glucagon pancreatic origin and does not pose a genotoxic risk to humans. GlucaGen (rDNA origin) was not tested in animal fertility studies. Studies in rats have shown that pancreatic glucagon does not cause impaired fertility. </p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_bb59c8f2-b6d3-4ede-8a53-9e9614d9b9ea"></a><a name="section-13"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2e64f2e2-c1b2-4425-8023-9f3f252753e2"></a><a name="section-13.1"></a><p></p>
<h2>16.1 How Supplied</h2>
<p class="First">GlucaGen is supplied as a sterile, lyophilized white powder in a vial, alone, or accompanied by Sterile Water for Reconstitution also in a vial (Diagnostic Kit or 10-pack). It is also supplied as GlucaGen HypoKit with a disposable prefilled syringe containing Sterile Water for Reconstitution.</p>
<p><span class="Bold">GlucaGen HypoKit includes:  <span class="Italics"><br></span></span>1 vial containing 1 mg (1 unit) GlucaGen (glucagon [rDNA origin] for injection)<br>1 disposable syringe containing 1 mL Sterile Water for Reconstitution<br>NDC 0169-7065-15</p>
<p><span class="Bold">GlucaGen Diagnostic Kit (NDC 0597-0260-10) includes:<br></span>1 vial containing 1 mg (1 unit) GlucaGen<span class="Sup"></span>(glucagon [rDNA origin] for injection)<br>NDC 0597-0053-01<br>1 vial containing 1 mL Sterile Water for Reconstitution<br>NDC 0597-0265-94</p>
<p><span class="Bold">GlucaGen Diagnostic Kit is also available as (NDC 55390-004-01) and includes:<br></span>1 vial containing 1 mg (1 unit) GlucaGen<span class="Sup"></span>(glucagon [rDNA origin] for injection)<span class="Bold"><br></span>NDC 55390-004-01<span class="Bold"><br></span>1 vial containing 1 mL Sterile Water for Reconstitution</p>
<p><span class="Bold">GlucaGen HypoKit (Two-Pack) includes: </span>2 packs of GlucaGen HypoKit, <br>Each HypoKit contains: <br>1 vial containing 1 mg (1 unit) GlucaGen (glucagon [rDNA origin] for injection) <br>1 disposable syringe containing 1 mL Sterile Water for Reconstitution<br>NDC 0169-7065-21</p>
<p><span class="Bold">The GlucaGen 10-pack includes:<br></span>10 vials, each containing 1 mg (1 unit) GlucaGen (glucagon [rDNA origin] for injection)<br>NDC 55390-004-10<br>NDC 0597-0053-45</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e73b3777-d509-4015-be58-3f12d64fa8b3"></a><a name="section-13.2"></a><p></p>
<h2>16.2 Recommended Storage</h2>
<p class="First"><span class="Bold">Before Reconstitution:</span><br>The GlucaGen package may be stored up to 24 months at controlled room temperature 20<span class="Sup">o</span> to 25<span class="Sup">o</span> C (68<span class="Sup">o</span> to 77<span class="Sup">o </span>F) prior to reconstitution. Do not freeze. Keep in the original package to protect from light. GlucaGen should not be used after the expiry date on the vials.</p>
<p><span class="Bold">After Reconstitution:</span><br>Reconstituted GlucaGen should be used immediately. <span class="Underline">Discard any unused portion</span>. If the solution shows any sign of gel formation or particles, it should be discarded. </p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_118ff1a2-7640-4068-a207-72335206a581"></a><a name="section-14"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First"> [S<span class="Italics">ee FDA-Approved Patient Labeling (Patient Instructions for Emergency Use).</span>]</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ecd14098-3fd0-4a20-bbf9-d7abaf3b9662"></a><a name="section-14.1"></a><p></p>
<h2>17.1 Physician Instructions</h2>
<p class="First">Refer patients and family members to the FDA-approved patient labeling for instructions describing the method of preparing and injecting GlucaGen. Advise the patient and family members to become familiar with the technique of preparing glucagon before an emergency arises. Instruct patients to use 1 mg for adults or ½ the adult dose (0.5 mg) for children weighing less than 55 lb (25 kg). To prevent severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, patients and family members should be informed of the symptoms of mild <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> and how to treat it appropriately. Family members should be informed to arouse the patient as quickly as possible because prolonged <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> may result in damage to the central nervous system. Patients should be advised to inform their physician when <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemic reactions</span> occur so that the treatment regimen may be adjusted if necessary.</p>
<p>No studies on the effects on the ability to drive and use machines have been performed. After diagnostic procedures, <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> has been reported infrequently. The patient’s ability to concentrate and react may be impaired as a result of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. This may present a risk in situations where these abilities are especially important, such as driving or operating machinery. Therefore, these activities should be avoided until the patient has had a meal with oral carbohydrates.</p>
<p>Date of issue: December 12, 2014<br>Version: 6</p>
<p><span class="Italics">GlucaGen<span class="Sup">®</span> and HypoKit<span class="Sup">® </span>are registered trademarks of Novo Nordisk A/S </span></p>
<p><span class="Italics">© 1998-2014 Novo Nordisk</span></p>
<p><span class="Bold">For information contact:<br>Boehringer Ingelheim Pharmaceuticals, Inc.<br></span>Ridgefield, CT 06877<span class="Bold"><br></span>1-800-243-0127</p>
<p><span class="Bold">Manufactured for:<br>Boehringer Ingelheim Pharmaceuticals, Inc.<br></span>Ridgefield, CT 06877</p>
<p><span class="Bold">By:<br></span>Novo Nordisk A/S<span class="Bold"><br></span>2880 Bagsvaerd, Denmark</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_0cbe48d0-7106-4ca8-9ab5-1c47f8f5b35c"></a><a name="section-15"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - GlucaGen diagnostic kit</h1>
<p class="First">NDC 0597-0260-10</p>
<p><span class="Bold">GlucaGen<span class="Sup">®</span></span></p>
<p>[glucagon (rDNA origin) for injection]</p>
<p>1 mg per vial</p>
<p>For intramuscular or intravenous injection</p>
<p><span class="Bold">GlucaGen® should be reconstituted<br>with Sterile Water for Reconstitution<br>immediately before use</span></p>
<p><span class="Bold">Single use only. Discard unused portion.<br>Protect from Light.</span></p>
<p><span class="Bold">See package insert for complete product<br>information.</span></p>
<p><span class="Bold">FOR DIAGNOSTIC USE ONLY - NOT INTENDED FOR<br>USE BY PATIENTS TO TREAT SEVERE<br><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">HYPOGLYCEMIA</span></span></p>
<p><span class="Bold">Rx ONLY</span></p>
<p><span class="Bold">Boehringer<br>Ingelheim</span></p>
<div class="Figure">
<a name="id969"></a><img alt="Diagnostic Kit Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ff16e4b1-3668-4cb4-91a4-77ee509cd6f6&amp;name=91272300-e7bb-4491-86db-e840126c888b-03.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_c27d1326-45d9-426d-98e8-51dcecc274fa"></a><a name="section-16"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - GlucaGen diagnostic kit - (10 Pack)</h1>
<p class="First">NDC 0597-0053-45</p>
<p>10 vials each containing 1 mg per vial</p>
<p><span class="Bold">GlucaGen<span class="Sup">®</span></span></p>
<p>[glucagon (rDNA origin) for injection]</p>
<p>1 mg per vial</p>
<p>For intramuscular or intravenous injection</p>
<p><span class="Bold">Protect from Light</span></p>
<p><span class="Bold">FOR DIAGNOSTIC USE ONLY - NOT INTENDED FOR<br>USE BY PATIENTS TO TREAT SEVERE <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">HYPOGLYCEMIA</span></span></p>
<p><span class="Bold">Rx ONLY</span></p>
<p><span class="Bold">Boehringer<br>Ingelheim</span></p>
<div class="Figure">
<a name="id996"></a><img alt="10 vial Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ff16e4b1-3668-4cb4-91a4-77ee509cd6f6&amp;name=91272300-e7bb-4491-86db-e840126c888b-04.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>GLUCAGEN 		
					</strong><br><span class="contentTableReg">glucagon hydrochloride kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0597-0260</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0597-0260-10</td>
<td class="formItem">1  in 1 KIT; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">Part #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem">1 VIAL, GLASS </td>
<td class="formItem">1 mL</td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem">1 VIAL, GLASS </td>
<td class="formItem">1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>GLUCAGEN 		
					</strong><br><span class="contentTableReg">glucagon hydrochloride injection, powder, for solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0597-0053</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>GLUCAGON HYDROCHLORIDE</strong> (glucagon) </td>
<td class="formItem">glucagon</td>
<td class="formItem">1 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem">107 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0597-0053-01</td>
<td class="formItem">1 mL in 1 VIAL, GLASS; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020918</td>
<td class="formItem">06/22/2005</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>WATER 		
					</strong><br><span class="contentTableReg">water liquid</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0597-0265</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem">1 mL  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0597-0265-94</td>
<td class="formItem">1 mL in 1 VIAL, GLASS; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020918</td>
<td class="formItem">06/22/2005</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020918</td>
<td class="formItem">06/22/2005</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>GLUCAGEN 		
					</strong><br><span class="contentTableReg">glucagon hydrochloride injection, powder, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0597-0053</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBCUTANEOUS, INTRAMUSCULAR, INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>GLUCAGON HYDROCHLORIDE</strong> (GLUCAGON) </td>
<td class="formItem">GLUCAGON</td>
<td class="formItem">1 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem">107 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0597-0053-45</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1 mL in 1 VIAL; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020918</td>
<td class="formItem">06/22/2005</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Boehringer Ingelheim Pharmaceuticals, Inc.
							(603175944)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Novo Nordisk (622920320)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Novo Nordisk A/S</td>
<td class="formItem"></td>
<td class="formItem">306711800</td>
<td class="formItem">MANUFACTURE(0597-0260, 0597-0053, 0597-0265, 0597-0053)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 12/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>ff16e4b1-3668-4cb4-91a4-77ee509cd6f6</div>
<div>Set id: ff16e4b1-3668-4cb4-91a4-77ee509cd6f6</div>
<div>Version: 1</div>
<div>Effective Time: 20141212</div>
</div>
</div> <div class="DistributorName">Boehringer Ingelheim Pharmaceuticals, Inc.</div></p>
</body></html>
